Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 15, 2001

View Archived Issues

Next 12 months predicted to be most productive period in BMS discovery and development history

Abbott terminates ABS-103 licensing agreement

Phytopharm's dementia treatment enters clinical testing

Phase Ib laboratory analysis complete of Helivax vaccine against H. pylori

Medarex and m-phasys collaborate on human antibody therapeutics development

Preclinical study supports use of Hemopure for acute blood loss following trauma

PRS-211095: a new neuroprotective dexanabinol analogue

Tolvaptan as an alternative to fluid restriction in hyponatremia

Primary endpoint reached in CART-1 trial of AGI-1067; data discussed in Anaheim

Phase II results of multigene DNA vaccine against malaria

Testosterone buccal tablet proves successful in phase III comparative trials

Active Biotech cleared to begin phase II trials of TTS in renal cell cancer

Development of VP-50406 discontinued for treatment of hepatitis C

Onco TCS pilot phase II trials expanded to include combination therapy with etoposide

AHA news: preliminary phase II data demonstrate significant increase in HDL cholesterol on JTT-705

Tezosentan in acute decompensated heart failure and acute coronary syndrome

Point Biomedical myocardial perfusion agent compares favorably to SPECT in phase II study

Antiarthritic agent with novel mechanism of action presented at ACR/ARHP meeting

Plenary VII: Late Breaking Clinical Trials webcast now available to DailyDrugNews.com readers

Sustained antiarthritic activity demonstrated in animal model for modified form of IL-1ra

Therapeutic potential of selective JNK inhibitor in epilepsy and stroke

General Hospital Corporation reveals novel method for treating neurodegenerative diseases

Cannabinoid antagonists claimed by Solvay for CNS, gastrointestinal and cardiovascular disorders

Ortho-McNeil synthesizes new calcium channel antagonists

Lipase inhibitors from Aventis useful for hyperlipidemia-related conditions

COX-2-inhibitory pyrazole derivatives identified at Pfizer

AtheroGenics patents VCAM-1 expression inhibitors and potential uses

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...